donepezil has been researched along with Diarrhea in 14 studies
Donepezil: An indan and piperidine derivative that acts as a selective and reversible inhibitor of ACETYLCHOLINESTERASE. Donepezil is highly selective for the central nervous system and is used in the management of mild to moderate DEMENTIA in ALZHEIMER DISEASE.
donepezil : A racemate comprising equimolar amounts of (R)- and (S)-donepezil. A centrally acting reversible acetylcholinesterase inhibitor, its main therapeutic use is in the treatment of Alzheimer's disease where it is used to increase cortical acetylcholine.
2-[(1-benzylpiperidin-4-yl)methyl]-5,6-dimethoxyindan-1-one : A member of the class of indanones that is 5,6-dimethoxyindan-1-one which is substituted at position 2 by an (N-benzylpiperidin-4-yl)methyl group.
Diarrhea: An increased liquidity or decreased consistency of FECES, such as running stool. Fecal consistency is related to the ratio of water-holding capacity of insoluble solids to total water, rather than the amount of water present. Diarrhea is not hyperdefecation or increased fecal weight.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The objective of this 10-week, randomized, double-blind, placebo-controlled multicenter study was to assess the efficacy and safety of donepezil for the treatment of cognitive dysfunction exhibited by children with Down syndrome (DS)." | 9.14 | Donepezil for treatment of cognitive dysfunction in children with Down syndrome aged 10-17. ( Escobar, L; Heller, JH; Kishnani, PS; Lott, I; McRae, T; Richardson, S; Spiridigliozzi, GA; Zhang, R, 2010) |
| "The objective of this 10-week, randomized, double-blind, placebo-controlled multicenter study was to assess the efficacy and safety of donepezil for the treatment of cognitive dysfunction exhibited by children with Down syndrome (DS)." | 5.14 | Donepezil for treatment of cognitive dysfunction in children with Down syndrome aged 10-17. ( Escobar, L; Heller, JH; Kishnani, PS; Lott, I; McRae, T; Richardson, S; Spiridigliozzi, GA; Zhang, R, 2010) |
| "(1) Donepezil can reduce memory loss, dry mouth, and constipation in nongeriatric affective patients, but may trigger mania; and (2) long-term follow-up will reveal the predictive value for dementia of donepezil's memory restoration in nongeriatric subjects." | 5.09 | Donepezil for psychotropic-induced memory loss. ( Comas-Díaz, L; Jacobsen, FM, 1999) |
| " This study evaluated the effects of pretreatment with the oral cholinesterase inhibitor and anti-Alzheimer's agent, donepezil (Aricept) on the hypokinetic, hypothermic and diarrhea-inducing effects of the irreversible long-acting cholinesterase inhibitor, diisopropylfluorophosphate (DFP) in adult Sprague-Dawley rats." | 3.73 | Anticholinesterase (DFP) toxicity antagonism by chronic donepezil: a potential nerve agent treatment. ( Davis, JM; Janowsky, DS; Overstreet, DH, 2005) |
| " Experiment 1 tested the effects of 5 mg/per day dosage on cognitive and EEG markers at 6-hour, 2-week and 4-week follow-ups." | 2.76 | Donepezil impairs memory in healthy older subjects: behavioural, EEG and simultaneous EEG/fMRI biomarkers. ( Balsters, JH; Bokde, AL; Brennan, S; Cassidy, SM; Delmonte, S; Fagan, AJ; Galli, A; Kilcullen, SM; Lai, R; Laruelle, M; Lawlor, B; Martin, MP; Meaney, JF; O'Connell, RG; Robertson, IH; Upton, N, 2011) |
| " Adverse events (AEs) were recorded throughout." | 2.75 | Safety and tolerability of donepezil in mild cognitive impairment: open-label extension study. ( Doody, RS; Ferris, S; Gao, J; Goldman, R; Murthy, AK; Salloway, S, 2010) |
| "Donepezil-treated patients showed significant benefits in activities of daily living over placebo on the Alzheimer's Disease Functional Assessment and Change Scale (mean change from baseline score effect size at week 24: donepezil 5 mg/d, -1." | 2.71 | Efficacy and tolerability of donepezil in vascular dementia: positive results of a 24-week, multicenter, international, randomized, placebo-controlled clinical trial. ( Black, S; Burns, A; Geldmacher, DS; Hecker, J; Kumar, D; Perdomo, C; Pratt, R; Román, GC; Salloway, S, 2003) |
| "Donepezil (Aricept) is a highly selective acetylcholinesterase inhibitors with a pharmacokinetic profile allowing once-daily dosing." | 2.42 | Donepezil (Aricept) for treatment of Alzheimer's disease and other dementing conditions. ( Geldmacher, DS, 2004) |
| "Donepezil is a synthetic noncovalent reversible inhibitor of acetylcholinesterase (AChE) for the treatment of mild to moderate dementia associated with Alzheimer's disease." | 2.40 | Donepezil: an anticholinesterase inhibitor for Alzheimer's disease. ( Shintani, EY; Uchida, KM, 1997) |
| "The objective was to investigate the frequency of adverse events (AE) as a cause for discontinuation of donepezil treatment for Alzheimer's dementia (DAT) in a geriatric memory unit." | 1.35 | [Adverse events causing discontinuation of donepezil for Alzheimer's dementia]. ( Carøe, TK; Moe, C, 2009) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 3 (21.43) | 18.2507 |
| 2000's | 7 (50.00) | 29.6817 |
| 2010's | 4 (28.57) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Davoren, JE | 1 |
| Garnsey, M | 1 |
| Pettersen, B | 1 |
| Brodney, MA | 1 |
| Edgerton, JR | 1 |
| Fortin, JP | 1 |
| Grimwood, S | 1 |
| Harris, AR | 1 |
| Jenkinson, S | 1 |
| Kenakin, T | 1 |
| Lazzaro, JT | 1 |
| Lee, CW | 1 |
| Lotarski, SM | 1 |
| Nottebaum, L | 1 |
| O'Neil, SV | 1 |
| Popiolek, M | 1 |
| Ramsey, S | 1 |
| Steyn, SJ | 1 |
| Thorn, CA | 1 |
| Zhang, L | 1 |
| Webb, D | 1 |
| Doody, RS | 1 |
| Ferris, S | 1 |
| Salloway, S | 2 |
| Goldman, R | 1 |
| Gao, J | 1 |
| Murthy, AK | 1 |
| Carøe, TK | 1 |
| Moe, C | 1 |
| Kishnani, PS | 2 |
| Heller, JH | 2 |
| Spiridigliozzi, GA | 2 |
| Lott, I | 1 |
| Escobar, L | 1 |
| Richardson, S | 1 |
| Zhang, R | 1 |
| McRae, T | 1 |
| Balsters, JH | 1 |
| O'Connell, RG | 1 |
| Martin, MP | 1 |
| Galli, A | 1 |
| Cassidy, SM | 1 |
| Kilcullen, SM | 1 |
| Delmonte, S | 1 |
| Brennan, S | 1 |
| Meaney, JF | 1 |
| Fagan, AJ | 1 |
| Bokde, AL | 1 |
| Upton, N | 1 |
| Lai, R | 1 |
| Laruelle, M | 1 |
| Lawlor, B | 1 |
| Robertson, IH | 1 |
| Sullivan, JA | 1 |
| Doraiswamy, PM | 1 |
| Krishnan, RR | 1 |
| Black, S | 1 |
| Román, GC | 1 |
| Geldmacher, DS | 2 |
| Hecker, J | 1 |
| Burns, A | 1 |
| Perdomo, C | 1 |
| Kumar, D | 1 |
| Pratt, R | 1 |
| Janowsky, DS | 2 |
| Davis, JM | 2 |
| Overstreet, DH | 2 |
| Shintani, EY | 1 |
| Uchida, KM | 1 |
| Carrier, L | 1 |
| Jacobsen, FM | 1 |
| Comas-Díaz, L | 1 |
| Lam, W | 1 |
2 reviews available for donepezil and Diarrhea
| Article | Year |
|---|---|
Donepezil (Aricept) for treatment of Alzheimer's disease and other dementing conditions.
Topics: Alzheimer Disease; Anorexia; Cholinesterase Inhibitors; Clinical Trials as Topic; Cognition Disorder | 2004 |
Donepezil: an anticholinesterase inhibitor for Alzheimer's disease.
Topics: Aged; Alzheimer Disease; Anorexia; Cholinesterase Inhibitors; Diarrhea; Donepezil; Drug Administrati | 1997 |
6 trials available for donepezil and Diarrhea
| Article | Year |
|---|---|
Safety and tolerability of donepezil in mild cognitive impairment: open-label extension study.
Topics: Adult; Aged; Aged, 80 and over; Amnesia; Cholinesterase Inhibitors; Cognition Disorders; Diarrhea; D | 2010 |
Donepezil for treatment of cognitive dysfunction in children with Down syndrome aged 10-17.
Topics: Adolescent; Behavior; Caregivers; Child; Cholinesterase Inhibitors; Cognition Disorders; Diarrhea; D | 2010 |
Donepezil impairs memory in healthy older subjects: behavioural, EEG and simultaneous EEG/fMRI biomarkers.
Topics: Aged; Analysis of Variance; Cholinesterase Inhibitors; Cognition; Cross-Over Studies; Diarrhea; Done | 2011 |
Donepezil for the treatment of language deficits in adults with Down syndrome: a preliminary 24-week open trial.
Topics: Adult; Appetite; Cholinesterase Inhibitors; Diarrhea; Donepezil; Dose-Response Relationship, Drug; D | 2003 |
Efficacy and tolerability of donepezil in vascular dementia: positive results of a 24-week, multicenter, international, randomized, placebo-controlled clinical trial.
Topics: Activities of Daily Living; Aged; Aged, 80 and over; Cardiovascular System; Cholinesterase Inhibitor | 2003 |
Donepezil for psychotropic-induced memory loss.
Topics: Adult; Ambulatory Care; Cholinesterase Inhibitors; Constipation; Depressive Disorder; Diarrhea; Dizz | 1999 |
6 other studies available for donepezil and Diarrhea
| Article | Year |
|---|---|
Design and Synthesis of γ- and δ-Lactam M
Topics: Allosteric Regulation; Amphetamine; Animals; Ataxia; Diarrhea; Dogs; Donepezil; Drug Design; Female; | 2017 |
[Adverse events causing discontinuation of donepezil for Alzheimer's dementia].
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Appetite; Cholinesterase Inhibitors; Diarrhea; Donepezil | 2009 |
Antagonism of anticholinesterase (DFP) toxicity by donepezil plus scopolamine: a preliminary study.
Topics: Animals; Behavior, Animal; Body Temperature; Cholinesterase Inhibitors; Diarrhea; Donepezil; Drug In | 2004 |
Anticholinesterase (DFP) toxicity antagonism by chronic donepezil: a potential nerve agent treatment.
Topics: Animals; Behavior, Animal; Body Temperature; Cholinesterase Inhibitors; Diarrhea; Donepezil; Hypokin | 2005 |
Donepezil and paroxetine: possible drug interaction.
Topics: Aged; Aggression; Akathisia, Drug-Induced; Antidepressive Agents, Second-Generation; Confusion; Diar | 1999 |
Pharmacological treatment of cognitive deficits in Alzheimer's disease.
Topics: Alzheimer Disease; Diarrhea; Donepezil; Humans; Indans; Nausea; Nootropic Agents; Piperidines; Vomit | 2002 |